Quince Therapeutics' (QNCX) "Buy" Rating Reaffirmed at D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a "Buy" rating for Quince Therapeutics (QNCX) with a price target of $4.00, indicating a potential upside of 145.40% from the current stock price.
• Quince Therapeutics' current average rating among analysts is "Buy", with a consensus target price of $8.14, despite recent earnings results missing consensus estimates.
• Hedge funds have increased their stakes in Quince Therapeutics, with several reporting significant percentage gains in their holdings over the past quarters.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report)'s stock had its "buy" rating restated by stock analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. They currently have a $4.00 price objective on the stock. D. Boral Capital's price target would suggest a potential upside of 145.40% from the company's current price.

A number of other brokerages also recently issued reports on QNCX. Citizens Jmp assumed coverage on shares of Quince Therapeutics in a report on Tuesday, August 5th. They issued a "strong-buy" rating and a $9.00 price target for the company. Zacks Research upgraded shares of Quince Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 26th. JMP Securities cut their price target on shares of Quince Therapeutics from $9.00 to $8.00 and set a "market outperform" rating for the company in a report on Tuesday, August 12th. Finally, Citigroup assumed coverage on shares of Quince Therapeutics in a report on Tuesday, August 5th. They issued an "outperform" rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $8.14.

Quince Therapeutics Stock Up 0.6%

QNCX stock opened at $1.63 on Friday. Quince Therapeutics has a one year low of $0.69 and a one year high of $2.45. The stock has a market capitalization of $87.55 million, a PE ratio of -1.50 and a beta of 0.99. The company has a debt-to-equity ratio of 1.45, a quick ratio of 5.00 and a current ratio of 5.00. The company has a fifty day moving average of $1.66 and a 200-day moving average of $1.39.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06). As a group, analysts expect that Quince Therapeutics will post -1.21 EPS for the current year.

Hedge Funds Weigh In On Quince Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC increased its holdings in Quince Therapeutics by 48.4% during the 1st quarter. Virtu Financial LLC now owns 43,332 shares of the company's stock valued at $58,000 after acquiring an additional 14,128 shares in the last quarter. Northern Trust Corp increased its holdings in Quince Therapeutics by 48.5% during the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company's stock valued at $94,000 after acquiring an additional 16,501 shares in the last quarter. Bridgeway Capital Management LLC increased its holdings in Quince Therapeutics by 20.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company's stock valued at $212,000 after acquiring an additional 22,200 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Quince Therapeutics during the second quarter worth about $37,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Quince Therapeutics during the fourth quarter worth about $57,000. 30.75% of the stock is currently owned by hedge funds and other institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.